Beyond HER2 and TROP2: How AbbVie's c-Met Top1i Antibody-Drug Conjugate Earned Two Breakthrough Designations
Dr. Dereck Mush, MD, MBA
Lucid Diagnostics
Molecular diagnostic tests designed for the early detection of esophageal precancer.
What they do
Lucid Diagnostics manufactures a non-invasive esophageal cell collection device paired with a molecular diagnostic test. This technology allows primary care physicians and gastroenterologists to screen patients with chronic reflux for esophageal precancer, preventing progression to lethal esophageal cancer.
The record
- Vertical
- Imaging & Diagnostics
- Sub-segment
- Esophageal cancer diagnostics
- Product type
- Diagnostics
- Stage
- Public
- Headquarters
- New York, USA
- Region
- North America
- Founded
- 2018
- Total funding
- $60M raised
Notable investors: PAVmed.
Also in Imaging & Diagnostics
Related on The Signal
Dr. Dereck Mush, MD, MBA
The MCED Inflection Point: What Galleri's FDA Panel Backing Means for Cancer Screening
Dr. Dereck Mush, MD, MBA
The Radiopharmaceutical Infrastructure Playbook: Why Telix's FDA Approval for Pixclara Redefines Neuro-Oncology Diagnostics and Theranostics
Dr. Dereck Mush, MD, MBAThe HealthTech Signal
The 8 Best AI Diagnostic Tools of 2026
AI diagnostics stopped being experimental. These eight tools are FDA-cleared, deployed at scale, and quietly changing how disease gets found.
Dr. Dereck Mush, MD, MBA